AstraZeneca Uses Priority Voucher To Speed Combo Towards Liver Cancer Approval

Long Wait For First Tremelimumab Approval Could Soon Be Over

AstraZeneca’s PD-L1/CTLA-4 combination could soon be rivalling Roche’s regimen, and may offer greater safety and tolerability for liver cancer patients.

Astrazeneca
AstraZeneca could gain its first approval for the immunotherapy combination by the end of 2022 - but rivals Roche have a head start in liver cancer. • Source: Alamy

After years of struggling to get a positive readout for its cancer immunotherapy candidate tremelimumab, AstraZeneca is in a hurry to get it approved and on the market, and could achieve that goal before the end of 2022 thanks to the use of a priority review voucher.

A biologics license application for tremelimumab has been accepted for priority review by the US Food and Drug Administration for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip